Bristol-Myers Squibb Promotes John E. Celentano to President of Health Care Group
Posted on: Friday, 2 December 2005, 15:00 CST
NEW YORK, Dec. 2 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company announced today that it has promoted John E. Celentano to president, Health Care Group. In this new assignment, Celentano will have responsibility for all of the company's non-pharmaceutical businesses, including Mead Johnson Nutritionals, ConvaTec and Bristol-Myers Squibb Medical Imaging. Celentano will report to Peter R. Dolan, chief executive officer, Bristol-Myers Squibb.
"John is an experienced executive with more than twenty years of diverse business experience and an outstanding track record of building the company's U.S. and international businesses," Dolan said. "He is a strategic leader with a broad understanding of the global health care environment and public policy issues. John's leadership skills, along with his knowledge of the health care industry, will be of great value in this new role."
Most recently, Celentano served as president, Latin America and Canada, for Bristol-Myers Squibb's pharmaceutical business. He holds an M.B.A. from Drexel University and a B.A. degree from the University of Delaware.
Earlier this year, Bristol-Myers Squibb Company reorganized under two operating units - Global Pharmaceutical Operations and the Health Care Group. Lamberto Andreotti was named executive vice president, Bristol-Myers Squibb and president, Worldwide Pharmaceuticals. The decision to consolidate the company's Health Care Group under the leadership of Celentano will help identify and capitalize on the strategic opportunities of those three businesses.
Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.
Bristol-Myers Squibb Company
CONTACT: Media: Tony Plohoros, Communications, +1-212-546-4379,tony.plohoros@bms.com, or Jeffrey Schoenborn, Communications, +1-212-546-2846,jeffrey.schoenborn@bms.com, or Investors: John Elicker, Investor Relations,+1-212-546-3775, or john.elicker@bms.com, or Blaine Davis, Investor Relations,+1-212-546-4631, or blaine.davis@bms.com
Web site: http://www.bms.com/
Source: PRNewswire-FirstCall
Related Articles
- Bristol-Myers Squibb Foundation to Award $1.4 Million in Grants to Bridge Gaps in Hepatitis C Awareness, Prevention and Care in Asia
- Bristol-Myers Squibb and AstraZeneca Announce Worldwide Collaboration to Develop and Commercialize Diabetes Compounds
- Bristol-Myers Squibb Plans to Build Biologics Facility in the U.S.
- FDA Grants Priority Review for Bristol-Myers Squibb's Investigational Oncology Treatment Dasatinib
- Bristol-Myers Squibb Submits New Drug Application for Dasatinib
- More Than 100,000 People Unite to Support AIDS Prevention and Care Programs Through Bristol-Myers Squibb 2005 World AIDS Day Campaign
- Bristol-Myers Squibb Company Reports Financial Results for the Third Quarter and First Nine Months of 2005, Reflecting Ongoing Investments in Strategy Aimed at Delivering Sustainable Growth
- Bristol-Myers Squibb Statement on FDA Advisory Committee Vote on ORENCIA(R) (Abatacept), an Investigational Selective Modulator of T-Cell Co-Stimulation for Rheumatoid Arthritis
- Bristol-Myers Squibb Announces Intent to Pursue FDA Approval of Pravachol(R) (Pravastatin Sodium) As an OTC Cholesterol-Lowering Therapy
 |
 |
User Comments (0)
RSS Feeds